secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066397
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q1 net loss $84.6M; reiterates zidesamtinib pivotal data in H1 2025, NDA by mid-2025
--------------------------------------------------------------------------------

- Cash $1.1B at March 31, 2025; expected to fund operations into 2028.
- Q1 net loss $84.6M; R&D expense $74.4M, G&A expense $20.4M.
- Zidesamtinib pivotal data for TKI pre-treated ROS1+ NSCLC in H1 2025; NDA submission by mid-2025.
- Neladalkib pivotal data for TKI pre-treated ALK+ NSCLC by year-end 2025; ALKAZAR Phase 3 start in H1 2025.
- Leadership promotions: Ruth Adams to SVP Clinical Ops, Joshua Horan to SVP Chemistry, Jessie Lin to SVP Corporate Strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017025066397/0000950170-25-066397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017025066397/nuvl-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer